Volume 129, Issue 6, Pages (June 2007)

Slides:



Advertisements
Similar presentations
Critical Roles of Lysosomal Acid Lipase in Myelopoiesis
Advertisements

by Jad I. Belle, David Langlais, Jessica C
Maintenance of the Hematopoietic Stem Cell Pool by CXCL12-CXCR4 Chemokine Signaling in Bone Marrow Stromal Cell Niches  Tatsuki Sugiyama, Hiroshi Kohara,
Volume 17, Issue 1, Pages (July 2015)
Volume 4, Issue 6, Pages (June 2009)
Volume 14, Issue 1, Pages (January 2014)
Volume 11, Issue 5, Pages (November 2012)
Continuous in vivo infusion of interferon-gamma (IFN-γ) enhances engraftment of syngeneic wild-type cells in Fanca–/– and Fancg–/– mice by Yue Si, Samantha.
On Hematopoietic Stem Cell Fate
Volume 129, Issue 6, Pages (June 2007)
Francesca Ficara, Mark J. Murphy, Min Lin, Michael L. Cleary 
Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized.
Volume 2, Issue 6, Pages (June 2008)
Sox17 Dependence Distinguishes the Transcriptional Regulation of Fetal from Adult Hematopoietic Stem Cells  Injune Kim, Thomas L. Saunders, Sean J. Morrison 
Volume 2, Issue 4, Pages (April 2008)
Cited2 Is an Essential Regulator of Adult Hematopoietic Stem Cells
Volume 8, Issue 5, Pages (May 2011)
Volume 3, Issue 4, Pages (October 2008)
Volume 15, Issue 6, Pages (June 2014)
Volume 17, Issue 10, Pages (December 2016)
Volume 30, Issue 4, Pages (October 2016)
Volume 19, Issue 2, Pages (August 2003)
Volume 30, Issue 3, Pages (September 2016)
The Use of Experimental Murine Models to Assess Novel Agents of Hematopoietic Stem and Progenitor Cell Mobilization  Kirsten E. Herbert, Jean-Pierre Lévesque,
Volume 11, Issue 3, Pages (September 2012)
Cytotoxic CD8+ T Cells Stimulate Hematopoietic Progenitors by Promoting Cytokine Release from Bone Marrow Mesenchymal Stromal Cells  Christian M. Schürch,
Volume 2, Issue 4, Pages (April 2008)
Volume 3, Issue 1, Pages (July 2014)
Volume 4, Issue 2, Pages (February 2003)
Georges Lacaud, Leif Carlsson, Gordon Keller  Immunity 
Mark J. Kiel, Melih Acar, Glenn L. Radice, Sean J. Morrison 
Volume 11, Issue 3, Pages (September 2012)
T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.
Volume 2, Issue 4, Pages (April 2008)
Volume 11, Issue 5, Pages (November 2018)
Volume 5, Issue 2, Pages (August 2009)
Genotypic and functional diversity of phenotypically defined primitive hematopoietic cells in patients with chronic myeloid leukemia  Ivan Sloma, Philip.
Emmanuelle Passegué, Erwin F. Wagner, Irving L. Weissman  Cell 
Ravindra Majeti, Christopher Y. Park, Irving L. Weissman 
Volume 9, Issue 1, Pages (July 2011)
Volume 10, Issue 3, Pages (March 2018)
Volume 149, Issue 1, Pages (March 2012)
Volume 27, Issue 5, Pages (November 2007)
Deletion of the Scl +19 enhancer increases the blood stem cell compartment without affecting the formation of mature blood lineages  Dominik Spensberger,
Volume 138, Issue 2, Pages (July 2009)
Volume 121, Issue 7, Pages (July 2005)
Volume 128, Issue 2, Pages (January 2007)
Volume 1, Issue 3, Pages (September 2007)
Volume 11, Issue 3, Pages (September 2012)
Volume 16, Issue 12, Pages (September 2016)
Masayuki Yamashita, Eriko Nitta, Toshio Suda  Cell Stem Cell 
Volume 6, Issue 3, Pages (March 2010)
Volume 7, Issue 6, Pages (December 2016)
Potential Pitfalls of the Mx1-Cre System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis  Talia Velasco-Hernandez, Petter.
Volume 4, Issue 2, Pages (February 2009)
Volume 17, Issue 4, Pages (October 2002)
Volume 1, Issue 6, Pages (December 2007)
Volume 3, Issue 2, Pages (August 2008)
Volume 1, Issue 6, Pages (December 2007)
Volume 2, Issue 1, Pages (January 2008)
Volume 9, Issue 4, Pages (October 2011)
Volume 8, Issue 1, Pages (January 2011)
Volume 8, Issue 4, Pages (April 2017)
Lineage tracing of murine adult hematopoietic stem cells reveals active contribution to steady-state hematopoiesis by Richard H. Chapple, Yu-Jung Tseng,
SLAM Family Markers Resolve Functionally Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent Progenitors  Hideyuki Oguro, Lei Ding, Sean J.
Volume 8, Issue 6, Pages (June 2017)
Volume 2, Issue 3, Pages (March 2008)
Expression of CD27 on Murine Hematopoietic Stem and Progenitor Cells
On Hematopoietic Stem Cell Fate
Volume 21, Issue 6, Pages (December 2004)
Presentation transcript:

Volume 129, Issue 6, Pages 1081-1095 (June 2007) Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment  Carl R. Walkley, Jeremy M. Shea, Natalie A. Sims, Louise E. Purton, Stuart H. Orkin  Cell  Volume 129, Issue 6, Pages 1081-1095 (June 2007) DOI: 10.1016/j.cell.2007.03.055 Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 1 Rapid Mobilization of Primitive Cells into the Peripheral Blood Following Deletion of Rb (A) Genomic PCR on whole BM from control (Mx−pRbfl/fl) and Rb-deficient animals (Mx+pRbΔ/Δ) at 6 and 12 weeks post-pIpC. (B) qRT-PCR for pRb, p130, and p107 on cDNA of control and Rb-deficient animals (n = 3 independent samples) 12 weeks post-pIpC. (C) Platelets and (D) leukocytes in PB following Rb deletion (time 0 = final dose of pIpC); n ≥ 4/time point; ∗p < 0.05. (E) Day 12 CFU-GEMM and CFU-GM/M from the PB of at 12 weeks post-pIpC; n ≥ 9/genotype; ∗p < 0.01. Value inside bars represents fold increase. (F) FACS profile and mean number of Lin−c-Kit+Sca-1+ (LKS+) in the PB; n > 4/genotype; ∗p < 0.01. Methylcellulose plates from day 12 of culture. Data expressed as mean ± SEM. Cell 2007 129, 1081-1095DOI: (10.1016/j.cell.2007.03.055) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 2 Myeloproliferation Following Rb Deletion (A) Femoral cellularity, n ≥ 3/genotype/time point. (B) Number of cells of each lineage/femur at 12 weeks post-pIpC; Granulocytes CD11b+Gr-1+, Macrophages CD11b+F4/80+, Immature B lymphoid IgM−B220+, Mature B lymphoid IgM+B220+, Mature Erythroid CD71−Ter119+, and Immature Erythroid CD71+Ter119+; n ≥ 6/genotype; ∗p < 0.01. (C) Number of phenotypic HSCs (LKS+CD34−/lo) and primitive progenitors/femur; 12 weeks post-pIpC; n ≥ 5/genotype; ∗p < 0.05. (D) Representative sections of tibiae at 12 weeks post-pIpC. (E) Volume of marrow space occupied by bone (BV/TV); 2 weeks post-pIpC; n ≥ 13/genotype; ∗p < 0.05. (F) Trabecular number/mm; ∗p < 0.05. (G) Separation of trabeculae; ∗p < 0.05. (H) Representative longitudinal sections of tibiae stained with Von Kossa technique (mineralized bone stained black). (I) Spleen cellularity; n ≥ 3/genotype/time point; ∗p < 0.01. (J) Number of cells of each lineage/spleen; 12 weeks post-pIpC; n ≥ 6/genotype; ∗p < 0.01. (K) Fold change in phenotypic LKS+ and LKS− in the spleen; n ≥ 3/genotype/time point; p < 0.05. (L) Representative spleen sections (12 weeks post-pIpC). Unless noted all data are expressed as mean ± SEM. Cell 2007 129, 1081-1095DOI: (10.1016/j.cell.2007.03.055) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 3 Increase in Progenitors in the Bone Marrow and HSCs/Progenitors in the Spleen of RbΔ/Δ Animals (A) Number of day 7 CFC per femur; n ≥ 5/genotype/time point; ∗p < 0.05. (B) Number of CFU-S12 from 1 × 105 whole BM cells; n = 5/genotype. (C) Splenic day 12 CFU-GEMM and CFU-GM/M at 12 weeks post-pIpC; n ≥ 9/genotype; ∗p < 0.01. Value inside bars is fold increase. (D) CFU-S8/spleen; n = 5/genotype; p < 0.05. (E) Percent PB chimerism at 17 weeks posttransplant from either 1 × 106 or 2 × 106 whole spleen cells from RbΔ/Δ animals 8 weeks post-pIpC with 2 × 105 WT BM cells; n = 5/genotype. (F) Lineage contribution of spleen-derived HSCs at 17 weeks. Data are expressed as mean ± SEM. Cell 2007 129, 1081-1095DOI: (10.1016/j.cell.2007.03.055) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 4 Loss of HSCs from the Bone Marrow Following Rb Deletion (A) HSC frequency and absolute number/femur; n = 4–5 recipients/cell dose/genotype; experiment was performed twice; data were pooled from two independent experiments for calculation of HSC frequency. Primary transplant data are from 6 months posttransplant. Secondary transplant data are from 3 months posttransplant. One thousand freshly isolated LKS+ were transplanted, and repopulating unit (RU) was calculated 6 months posttransplant; n = 5 recipients/cell dose/genotype. (B) Number of CFDA-SE-labeled cells in the BM of recipients 16 hr after injection; BM from 12 weeks post-pIpC; n = 5 recipients/genotype. (C) Apoptotic cells in the LKS+ and LKS− populations; n = 9/genotype; p < 0.05. Data are expressed as mean ± SEM. Cell 2007 129, 1081-1095DOI: (10.1016/j.cell.2007.03.055) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 5 Myeloid-Restricted Rb Deletion Does Not Result in a Myeloproliferation (A) BM analysis; n ≥ 6/genotype. (B) Phenotypic primitive progenitors/femur; n ≥ 6/genotype. (C) Number of osteoclasts/femur; 6 weeks post-pIpC; n = 3/genotype. (D) Number of osteoclasts/spleen; 6 weeks post-pIpC; n = 3/genotype. (E) Rb-excision analysis of osteoclasts and macrophages derived from either Mx-Cre mutants of Lysozyme-M-Cre−pRbfl/fl mutants; n ≥ 3/genotype. Representative photographs of osteoclast and macrophage cultures (original magnification 10×). Data are expressed as mean ± SEM. Cell 2007 129, 1081-1095DOI: (10.1016/j.cell.2007.03.055) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 6 A pRb-Dependent Interaction between Myeloid Cells and the Bone Marrow Microenvironment Causes Myeloproliferation (A) Wild-type BM was transplanted into unexcised Mx-Cre−pRbfl/fl and Mx-Cre+pRbfl/fl recipients, and 5 weeks posttransplant recipients received pIpC. Recipients were analyzed at 8 (n = 3/genotype) and 20 weeks (n = 4/genotype) post-pIpC. Data are expressed as fold change of Mx+ recipients compared to Mx−Cre−pRbfl/fl recipients (normalized to 100%). Data are shown from 8 weeks post-pIpC (comparable results at 20 weeks). (B) Sex-mismatched Lysozyme-M-Cre+pRbfl/fl BM was transplanted into unexcised Mx-Cre−pRbfl/fl and Mx-Cre+pRbfl/fl recipients, and 5 weeks posttransplant pIpC was administered. Data are expressed as fold change of Mx+ recipients compared to Mx-Cre−pRbfl/fl recipients (normalized to 100%). † = approximate time of analysis post-pIpC; n = 11 Mx-Cre+ recipients in three independent experiments (two found dead 2 weeks post-pIpC); n = 10 Mx-Cre− control recipients. (C) Comparison of spleen weights amongst groups. (D) Splenic hematopoiesis in Mx-Cre+pRbfl/fl recipients of Lysozyme-M-Cre+pRbfl/fl bone marrow. Data are expressed as fold change compared to Mx-Cre−pRbfl/fl recipients (normalized to 100%). Cell 2007 129, 1081-1095DOI: (10.1016/j.cell.2007.03.055) Copyright © 2007 Elsevier Inc. Terms and Conditions